Background: In the Ph 3 PACIFIC study of durvalumab (durva) versus placebo (pbo) in pts with stage III, locally advanced (LA), unresectable NSCLC after concurrent chemoradiotherapy (cCRT), PFS was significantly longer with durva (stratified HR 0.52; 95% CI 0.42-0.65; P < 0.0001). This exploratory analysis characterizes outcomes based on time from completing RT to Tx. Methods: PACIFIC (NCT02125461) was a randomized, double-blind, all-comers study of LA NSCLC pts with WHO PS 0/1 who did not progress after 2 cycles of platinumbased cCRT. Pts were stratified by age, sex and smoking history and randomized (2:1) to durva 10 mg/kg IV Q2W or pbo up to 12 months. Co-primary endpoints were PFS (BICR, RECIST v1.1) and OS (not available). Secondary endpoints included ORR, time to death/distant metastases (TTDM) and safety. We investigated potential associations between time to randomized Tx (<14 or 14 days) with efficacy and safety. Results: As of Feb 13, 2017, 713 pts were randomized, 26% within 14 days of RT. Baseline characteristics between the durva and pbo arm were well balanced in both the <14 and 14 days groups. PFS benefit with durva compared to pbo was observed regardless of timing from RT to randomization (<14 days: median NR vs 4.8 months, HR ¼ 0.39, 95% CI: 0.26-0.58; 14 days: median 14.0 vs 5.6 months, HR ¼ 0.63, 95% CI: 0.49-0.80). In addition, TTDM (<14 days: HR ¼ 0.33, 95% CI: 0.20-0.55; 14 days: HR ¼ 0.70, 95% CI: 0.51-0.95) and ORR (<14 days: 34.2% vs 16.4%; 14 days: 26.5% vs 15.8%) favored durva, regardless of time to randomization. There were no reported differences in safety with durva based on time to randomization, with incidences of any-cause grade 3/4 AEs (34.2% vs 31.3%) and SAEs (30.0% vs 28.2%) comparable across subgroups. In contrast, earlier randomization in the pbo arm was associated with increased rates of grade 3/4 AEs (33.3% vs 25.9%) and SAEs (33.3% vs 19.0%). Early randomization had minimal impact on grade 3 pneumonitis/radiation pneumonitis with durva (4.2% vs 4.5%). Conclusions: Durva provided clinical benefit compared to pbo, regardless of time from RT to randomization. There was no meaningful difference in safety, including high grade AEs, in durva-treated patients randomized within 2 weeks from RT versus later.
Background: Concurrent chemo-radiotherapy (cCRT) is the preferred treatment for most stage III NSCLC, with 5 year survival of 25-35%. Recent dose-escalated radiotherapy (RT) trials report a high incidence of cardiac events (CTCAE 3 of 11 -23%) in NSCLC. However, real world data on the incidence of cardiac events are lacking. Methods: In this multicenter retrospective cohort study a thorough patient file search was carried out in all consecutive pts treated with (C)RT for stage III NSCLC between 2006 -2013 The primary endpoint of this study was incidence of new cardiac event (CTCAE 2) within five years after (C)RT. Secondary we evaluated risk factors for cardiac events. Results: 474 pts with stage III NSCLC were eligible. 391 were treated with cCRT, 69 with sequential CRT, 8 with lobectomy and/or RT and 6 are unknown. 30% of the pts had a cardiac history; mostly consisting of coronary artery disease (13.1%), atrial arrhythmia (7.4%) and chronic heart failure (4.2%). In 5 years of follow-up 151 pts (31.9%) developed a new cardiac events with a median time to event of 8 months (range 0 -59). The most common cardiac events were arrhythmia (14.6%), heart failure (7.6%) and symptomatic coronary artery disease (6.8%). On multivariate analysis preexistent cardiac comorbidity (hazard ratio [HR] 1.72; 95% CI 1.07 -2.78; P ¼ 0.02), WHO-PS 2 (HR 1.72; 95% CI 1.07 -2.78; P ¼ 0.03), male gender (HR 1.43; 95% CI 1.01 -2.02; P ¼ 0.04) and age 70 (HR 1.42; 95% CI 1.018 -1.98; P ¼ 0.03) were significantly associated with a cardiac event. Within the subgroup of pts without pre-existent cardiac comorbidity (N ¼ 311), 27.1% developed a cardiac event and only age 70 was a significant predictor (HR 1.78; 95% CI 1.15 -2.75; P ¼ 0.01).
Conclusions: Approximately one third of stage III NSCLC pts treated in daily clinical practice develop a new cardiac event within 5 years after (C)RT. Pre-existent cardiac comorbidity, WHO-PS 2, age 70 and male gender are absolute risk factors for the development of a cardiac event. Because cardiac events cause a high burden of morbidity and can influence quality of life, screening for cardiac comorbidity and events, especially in the first year after treatment should be considered. Legal entity responsible for the study: Maastricht University Medical Center (MUMCþ). Funding: Has not received any funding. Disclosure: A-M.C. Dingemans: Other from Roche/Genentech, MSD Oncology, AstraZeneca, Pfizer, Lilly, other from Boehringer Ingelheim, Bristol-Myers Squibb, Clovis Oncology, outside the submitted work. All other authors have declared no conflicts of interest.
1365PD Screening for brain metastases (BM) in patients (pts) with stage III non-small cell lung cancer (NSCLC), magnetic resonance imaging (MRI) or dedicated contrast-enhanced computed tomography (dCE-CT)? A prospective observational study
Methods: Observational prospective multicentre study (3 Dutch centers, (NTR3628). Inclusion: all consecutive neurologically asymptomatic stage III (based on 18 FDG-PET) NSCLC pts with a dCE-CT brain incorporated in the 18 FDG-PET and an additional brain MRI. Demographics, brain imaging results and development of BM in follow-up (FU) were collected. Both MRI and 18 FDG-PET-CE-CT were reviewed by an experienced neuroradiologist. Primary endpoint: % pts with BM on MRI without suspect lesions on dCE-CT. 118 pts were needed to show a clinically relevant considered difference of 2%. Secondary endpoints: % of pts with BM on dCE-CT, % of pts with BM 1 year of a negative staging MRI. Results: 118 pts were enrolled between 12-'12 until 12-'16, and were followed until 12-'17. During the year of FU 30 extra pts were included. In total 148 pts were included: 59% male; mean age 68 years, 84% WHO PS 0-1 and 44% adenocarcinoma. Median time (range) between 18 FDG-PET-CE-CT and MRI was 13 (0 -57) days. 5 of the first 118 pts (4.2%) had a solitary BM on MRI despite no suspect brain lesions on dCE-CT. In total 7/154 pts (4.5%) had a BM on MRI without suspect lesions on dCE-CT. In retrospect, in one of these 7 pts a solitary BM could be identified on the 18 FDG-PET-CE-CT. 16 (7%) of the screened pts with extracranial stage III were excluded because BM were already detected on dCE-CT brain. Of the 118 pts with a FU of 1 year, 10 (8.5%) developed BM 1 year after a negative staging brain MRI. Background: Tobacco smoking is the major risk factor for lung cancer. However, approximately 10% of patients diagnosed with lung cancer have never smoked and knowledge of their characteristics and survival remain limited. Specific genetic alterations, e.g. ALK (anaplastic lymphoma kinase) rearrangements and EGFR (epidermal growth factor receptor) mutations, are more common in never-smoking lung cancer patients than in current or former smokers. We aimed to investigate characteristics of patients with different smoking history and estimate their lung cancer-specific survival.
Methods: This study was based on data from the Lung Cancer Database Sweden generated by record linkage between the Swedish National Lung Cancer Register and other population-based registers. Patients diagnosed with primary non-small cell lung cancer between 2002 and 2016 were included. The Kaplan-Meier method was used to estimate lung cancer-specific survival by smoking history (never-smokers, former smokers, and current smokers).
Results: In total, 41,262 patients with lung cancer were included, of those 4,624 (11.2%) had never smoked. Never-smokers were older at time of the diagnosis (median: 73 years, Inter Quartile Range (IQR)¼63-80) than current smokers (median: 67 years, IQR¼61-73) and former smokers (median: 72 years, IQR¼66-78). Women were overrepresented among never-smokers (66%) than among current (49%) and former smokers (43%). Adenocarcinoma was the most frequent histological subtype in all groups, but was proportionally more frequent in never-smokers (77%) compared to current smokers (52%) and former smokers (57%). The estimated overall (all stages) 2-year cause specific lung cancer survival was higher in never-smokers (35.9%, 95% CI 34.4 -37.5) than among current smokers (29.4%, 95% CI 28.7 -30.2) and former smokers (30.7%, 95% CI 30.0 -31.4).
Conclusions:
The observed longer survival and the difference in histopathology suggest that tumours in never-smokers have a different pathogenesis and a different behaviour than tobacco-associated lung cancer. In further analyses, we will examine observed differences in outcomes in more detail, including the modifying role of other prognostic factors.
Legal entity responsible for the study: Results: PLELC preferentially affects the young (< 60 years old: 71.8%) nonsmokers (72.9%), without significant difference in gender. The median follow-up time was 15 months (1-37 months) for the whole group and most patients were in the early stage with opportunity of operation (50.6%). For the advanced stage group, patients mainly received chemotherapies and radiotherapies, the 0.5-year and 1.5-year PFS rates were 61% and 29%, respectively. The TNM stage (P ¼ 0.014) and performance status (PS) (P ¼ 0.040) were associated with PFS significantly in the univariate analysis, while TNM stage was an independent prognostic factor in multivariate analysis (P ¼ 0.026).
In the subtype analysis, patients in the advanced stage receiving Gemcitabine plus platinum (GP group) or Paclitaxel plus platinum (TP group) had better PFS than Pemetrexed plus platinum (PP group) (P ¼ 0.005).
Conclusions: PLELC had a better prognosis compared with other types of non-small cell lung cancer (NSCLC) and was sensitive to radiotherapy and chemotherapy. The current results recommended that the GP and TP should be used as first-line treatment of PLELC. The TNM stage and PS were predictive in prognosis of PLELC patients.
